Compare KODK & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KODK | DBVT |
|---|---|---|
| Founded | 1880 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.0M | 948.8M |
| IPO Year | 1994 | 2014 |
| Metric | KODK | DBVT |
|---|---|---|
| Price | $8.39 | $15.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.04 |
| AVG Volume (30 Days) | ★ 876.7K | 302.7K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,114,000,000.00 | $5,636,000.00 |
| Revenue This Year | N/A | $35.04 |
| Revenue Next Year | N/A | $2,360.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 35.77 |
| 52 Week Low | $4.94 | $8.51 |
| 52 Week High | $14.87 | $26.19 |
| Indicator | KODK | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 32.26 | 40.22 |
| Support Level | $8.01 | $12.63 |
| Resistance Level | $9.01 | $17.78 |
| Average True Range (ATR) | 0.46 | 1.09 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 7.86 | 17.79 |
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.